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Abstract
Background: Some patients with chronic abdominal pain suffer from an anterior cutaneous nerve entrapment
syndrome (ACNES). This somewhat illusive syndrome is thought to be caused by the entrapment of end branches
of the intercostal nerves residing in the abdominal wall. If ACNES is suspected, a local injection of an anesthetic
agent may offer relief. If pain is recurrent following multiple-injection therapy, an anterior neurectomy entailing
removal of the entrapped nerve endings may be considered. After 1 year, a 70% success rate has been reported.
Research on minimally invasive alternative treatments is scarce. Pulsed radiofrequency (PRF) treatment is a relatively
new treatment for chronic pain syndromes. An electromagnetic field is applied around the nerve in the hope of
leading to pain relief. This randomized controlled trial compares the effect of PRF treatment and neurectomy in
patients with ACNES.
Methods: Adult ACNES patients having short-lived success following injections are randomized to PRF or
neurectomy. At the 8-week follow-up visit, unsuccessful PRF patients are allowed to cross over to a neurectomy.
Primary outcome is pain relief after either therapy. Secondary outcomes include patient satisfaction, quality of life,
use of analgesics and unanticipated adverse events. The study is terminated 6 months after receiving the final
procedure.
Discussion: Since academic literature on minimally invasive techniques is lacking, well-designed trials are needed to
optimize results of treatment for ACNES. This is the first large, randomized controlled, proof-of-concept trial comparing
two therapy techniques in ACNES patients. The first patient was included in October 2015. The expected trial deadline
is December 2017. If effective, PRF may be incorporated into the ACNES treatment algorithm, thus minimizing the
number of patients requiring surgery.
Trial registration: Nederlands Trial Register (Dutch Trial Register), NTR5131 (http://www.trialregister.nl/trialreg/admin/
rctview.asp?TC=5131). Registered on 15 April 2015.
Keywords: Abdominal pain, Randomized controlled trial, Chronic pain, Pain management, Surgical procedures,
Operative, Pulsed radiofrequency treatment
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Background
Chronic abdominal pain originating in the abdominal wall
is termed chronic abdominal wall pain (CAWP). A CAWP
syndrome may be caused by the anterior cutaneous nerve
entrapment syndrome (ACNES). At present, ACNES is still
often neglected as a possible cause of abdominal pain and
discomfort and a frequently overlooked diagnosis [1, 2].
An exact pathophysiological explanation of the syndrome
is currently lacking but may be related to alterations in
abdominal wall neuroanatomy.
The abdominal wall is sensory innervated by anterior
and lateral cutaneous branches of the anterior rami of
the thoracic intercostal nerves (7th to 12th) [3]. In
ACNES, normal function of one or more cutaneous
branches of the thoracic intercostal nerves is disturbed by
a hitherto unidentified event [3]. If ACNES is suspected,
current treatment options include analgesics, subfascial
injections of a local anesthetic (whether or not combined
with a long-acting corticosteroid), transcutaneous elec-
trical nerve stimulation (TENS) and surgical interventions
such as anterior and posterior neurectomy. Injection ther-
apy is effective in one third of patients in the long term
[4]. A neurectomy is usually considered in the remaining
two thirds with a reported 70% success rate [5].
Although neurectomy is effective in most patients, a
less-invasive procedure may be of potential benefit. Pulsed
radiofrequency (PRF) is a relatively minimally invasive
treatment that was initially designed as a less destructive
approach when compared to radiofrequency (RF) therapy.
Using the intermittent administration of high-frequency
currents, tissue temperatures do not exceed 42 °C, thus
preventing neuronal damage [6, 7]. A number of clinical
studies have shown potential as levels of chronic pain in a
variety of pain syndromes were significantly reduced [8, 9].
Evidence regarding the use of PRF in ACNES is limited to
two case reports on PRF treatment of the dorsal root
ganglion (DRG) resulting in pain reduction and improved
quality of life [10, 11].
The objective of the present paper is to discuss a ran-
domized trial comparing PRF with neurectomy as treat-
ment options in ACNES. Neurectomy is nowadays
considered the “gold standard” treatment but less invasive
methods may potentially be of benefit.
Methods
Trial design
This prospective, multicentre, non-blinded, proof-of-
concept, randomized controlled trial (with a one-way op-
tional crossover at 8 weeks) is performed in the SolviMáx
Center of Expertise for ACNES and Center of Excellence
for Abdominal Wall and Groin Pain and Maasziekenhuis
Pantein, Boxmeer, The Netherlands. SolviMáx is a subdiv-
ision of the Surgical Department of Máxima Medical Cen-
ter (MMC), a teaching hospital situated in the southern
part of The Netherlands. The Dutch Ministry of Health,
Welfare and Sport has certified SolviMáx as a Center of
Expertise for ACNES treatment. The trial will be based
on a clinical proof-of-concept design in order to inves-
tigate a potential difference in pain relief following
either PRF treatment or an anterior neurectomy in
ACNES. Furthermore, it is designed to attain more
knowledge on the use of PRF on peripheral nerves and
to detect possible side effects.
The present trial follows the guidelines of the Declar-
ation of Helsinki (version 19 October, 2013). The protocol
(protocol number NL53171.015.15) is approved by the
Medical Ethics Committee of MMC. The study protocol
(version 1) is registered at www.trialregister.nl (NTR regis-
tration number: 5131, date of registration 15 April 2015).
The present paper is written according to the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) 2013 Statement for reporting a clinical
trial protocol [12]. The SPIRIT Checklist is provided as
Additional file 1.
Participants
Patient enrollment started in October 2015. Patients
are identified at the two hospital facilities. Criteria for
the diagnosis ACNES are (1) a constant site of tender-
ness that is superficially located covering a fingertip-
sized point of maximal pain at the lateral border of the
rectus abdominis muscle, (2) a somewhat larger area of
altered skin sensation covering this tender point and
(3) observing that tenderness increases by abdominal
muscle tensing using Carnett’s test [13, 14]. Only adult
patients (over 18 years old) diagnosed with unilateral
ACNES and having temporary success from an injection
regimen will be invited for participation. In ACNES, a
treatment regimen consists of local abdominal wall
infiltration using 5–10 mL lidocaine as described in our
earlier studies [4, 15]. “Temporary” is defined as having
more than 50% pain reduction for at least 1 week after
such a local infiltration although symptoms recur after-
wards (refractory ACNES). Sixty-six patients (male or
female) will be enrolled in the trial. Patients are not
eligible if pain is caused by surgical scar-related pain
syndromes (i.e., point of maximum pain is located at
the site of a surgical scar) or due to recent intra-
abdominal pathology. Presence of other chronic pain
syndromes including fibromyalgia, dystrophy, chronic
low back pain, impaired communication, a previous
spinal surgical procedure at or between vertebral levels
T7 and L1 are also exclusion criteria. A full list of
inclusion and exclusion criteria is given in Table 1.
Once eligibility is determined, patients are counseled
on the specifics of the study and are given a number of
days prior to providing consent.
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Interventions
PRF arm
Patients will be randomized to one arm of treatment,
either PRF or an anterior neurectomy. Patients assigned
to the PRF arm will visit departments of pain manage-
ment of both hospitals for PRF treatment. While supine,
a maximal point of pain is determined by asking and by
a physical examination. In ACNES, there is characteris-
tically a small (<2-cm2) constant site of anterior abdom-
inal tenderness. Following marking, the skin is prepped
with betadine and draped. Ultrasound (US) is used to
locate the anterior fascia of the rectus abdominis muscle.
The skin is locally anesthetized using 1% lidocaine. A
straight, sharp RF cannula (SMK Pole needle 54 mm with
5-mm active tip, Cotop International BV, Amsterdam, The
Netherlands) is inserted at an approximately 45° angle
through the skin (Fig. 1). The tip of the cannula is then
positioned between the anterior and posterior fascia of the
rectus abdominis muscle. Electrical impedance is checked
confirming a normal, closed electrical circuit. Subse-
quently, the sensation testing mode (50 Hz, 0.3–0.5 V) is
started. As the nerve is often not visible using US, this
step is crucial for nerve localization. Sensations such as
paresthesia, numbness or prickly sensations should
occur at less than 0.5 V if the needle’s position is cor-
rect [16]. The cannula is subsequently connected to the
PRF Generator (G4, Cosman Medical, MA, USA) using
the following settings: 45 V, <42 °C, 20 msec and 2 Hz.
Treatment is applied for 6 min.
Neurectomy arm
Patients assigned to the neurectomy arm will be oper-
ated on in a daycare setting. The area of maximal pain is
identified and marked. Once general anesthesia is ad-
ministered, the anterior sheath of the rectus abdominal
muscle is exposed via a ±5-cm transverse skin incision.
The neurovascular bundle penetrating into the subcuta-
neous fat through the pre-existent fascial foramen is
identified (Fig. 2). The fascia is widened and the bundle
and all its branches within a 5-cm radius are ligated and
removed. Accompanying vascular structures are also
ligated or coagulated. The sheath as well as the remain-
der of the wound are closed in layers using absorbable
suturing material.
Medication
“Escape” medication as currently used for pain reduction
is allowed to be continued during the entire study
period. In daily clinical practice, patients who underwent
a neurectomy are always allowed to take analgesics in
the postoperative period. Both groups are allowed to
take medications according to their own need whereas
quantities are tabulated.
Outcomes
The primary objective is to compare the effect of PRF
with a neurectomy in terms of pain relief at the 8-week
follow-up. The outcome is measured using the Numeric
Pain Rating Scale (NPRS, 0 = no pain and 10 = excruciat-
ing). Pain is measured at t0, before intervention and
8 weeks after allowing the determination of short-term
efficacy (t1) as shown in the schedule of enrollment,
interventions and assessments, according to the SPIRIT
Statement (Fig. 3). Long-term efficacy is measured at
6-month follow-up (t2). Success is defined as more than
50% NPRS pain reduction following intervention.
Secondary outcomes include the effect of PRF or
neurectomy on quality of life, disability, neuropathic
characteristics, medication usage and satisfaction. The
Short Form Health Survey-12 questionnaire (SF-12) is
used for measuring quality of life and interference
from pain [17]. Patient disability will be measured
with the Pain Disability Index (PDI) and the Brief
Pain Inventory (BPI) [18, 19]. The Douleur Neuro-
pathique (DN4) is used in order to discriminate be-
tween neuropathic and non-neuropathic pain [20].
Table 1 Subject inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Patient is diagnosed with
unilateral anterior cutaneous
nerve entrapment syndrome
(ACNES)
• Patient has surgical scar-related pain
syndromes
• Eligible for neurectomy
(i.e., having temporarily
success using injection
therapy)
• Patient has recent intra-abdominal
pathology
• Patient >18 years old • Patient has other chronic pain
syndromes (such as fibromyalgia,
dystrophy, chronic low back pain)
• Patient is able to provide
written informed consent
• Patient has other neuropathic
diseases
• Patient is willing to
participate in the follow-
up schedule and protocol
• Patient has impaired communication
• Patient has participated in another
clinical investigation within 30 days
• Patient has had a spinal surgical
procedure at or between vertebral
levels T7 and L1
• Patient has been diagnosed with
cancer in the past 2 years, except
for skin malignancies
• Female patient of childbearing
potential is pregnant/nursing or
plans to become pregnant
during the course of the trial
• Significant anatomic deformity
(either congenital or acquired)
• Language barrier
• Allergy to local anesthetics
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Medication usage prior to, and after, treatment will
be recorded using World Health Organization (WHO)
pain steps. Patient satisfaction is recorded using the
Patient Global Impression of Change (PGIC, 1 very
much worse to 7 very much improved) and Verbal
Rating Scales methodology (VRS, 1 = “I am very satis-
fied” and 5 = “Pain is worse after treatment”) [4, 21].
All adverse events (AEs) reported spontaneously by
the patient, or observed by the investigators or their
staff, will be recorded.
Data handling
The investigators and co-investigators will make every
reasonable effort to protect the confidentiality of the
patients participating in the trial. Patients will not be iden-
tified by name, social security number, address, telephone
number, or any other direct personal identifier. A unique
identification code will be assigned to each patient partici-
pating in this trial. Information about the code will be kept
in a secure location. Data storage will reside at the coord-
inating site, MMC, in locked offices. Sites will retain
collected data for a minimum of 15 years. All electronic
data will be password-protected on computers stored in
locked offices. Access to patient information will be
limited to trial personnel only.
Sample size
Sample size estimation is based on a “responder” ana-
lysis, as recommended by the Initiative on Methods,
Measurement and Pain Assessment in Clinical Trials
(IMMPACT) Group recommendations [21]. Effect sizes
were estimated on the basis of published academic
literature. Neurectomy is considered successful in 70%
[13, 22–25]. Regarding the potential efficacy of PRF
treatment, a mean effect size was estimated at 30%.
There is no available academic literature apart from two
case reports on the use of PRF in ACNES patients. The
targeted effect size is a difference in proportion responding
to treatment (neurectomy versus PRF) of 40%; i.e., 70%
responding in neurectomy the group versus 30% in the
PRF group. Using G*Power 3.1.7 software, 80% power and
a two-tailed alpha of 5%, 58 participants are needed to
demonstrate a potential effect of either type of treatment
on pain relief. With an allowance for attrition of 10% in
both arms at 6-month follow-up, we will aim to recruit a
total of 66 patients.
Randomization
After enrollment and completing the baseline question-
naires, patients are randomly assigned (1:1 – PRF:neur-
ectomy) to one of two treatment groups following a
computer-generated list of random numbers by blocks
of 8. Randomization is stratified by treatment site loca-
tion (Boxmeer or Veldhoven). The allocation sequence
is concealed from the enrolling researcher and asses-
sing participants in sequentially numbered, opaque and
sealed envelopes, prepared by a secretary with no
involvement in the trial. One central coordinating
investigator (RM) is responsible for enrolling patients
and is the only investigator allowed to inform the inde-
pendent secretary of newly enrolled patients.
Blinding
Blinding of patients, surgeons and pain specialists is
not possible due to the characteristics of both treat-
ments (minimally invasive treatment without general
anesthesia versus invasive treatment with the use of
general anesthesia).
Fig. 1 Ultrasound-guided placing of the pulsed radiofrequency (PRF)
cannula at the tender point
Fig. 2 Intraoperative view of a neurovascular bundle (loop) and a
nearby branch (loop) perforating the fascial foramina of the anterior
sheath of the abdominal rectus muscle
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Statistical methods
All analyses are performed using the Statistical Package
for the Social Sciences (SPSS) version 21 for Windows.
Categorical variables are described as frequencies.
Continuous data are tested for normality and are pre-
sented as means with standard deviation (±SD) or me-
dian values (range) as appropriate. The primary outcome
measure is pain relief using the NPRS as compared to
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT
Pre-
intervention
0 8 wk
8 wk post 
crossover
6 months
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Pulsed Radiofrequency X X X
Neurectomy X X X
Cross-over group X X
ASSESSMENTS:
Age X
Gender X
Body Mass Index X
Pain Measurement (NPRS) X
X X X
Quality of Life (SF-12) X X X X
Functional Assessment 
(BPI) 
X X X X
Douleur Neuropathique 
(DN4) 
X X X X
Patient Satisfaction 
(PGIC) 
X X X
Patient Satisfaction (VRS) X X X
Pain disability (PDI) X X X X
Crossover decision +
Complications + + +
Fig. 3 Content for the schedule of enrollment, interventions and assessments, according to the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Statement [12]
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the preintervention pain levels (t0). Data of the PRF and
neurectomy groups will be compared using the Student’s
t test or the Wilcoxon signed-rank test, as appropriate.
Secondary outcomes will be compared between groups at
various time points (baseline, 8-week follow-up and
6-month follow-up). They will be compared to preinter-
vention values using Student’s t test or the Wilcoxon
signed-rank test as appropriate. A p value < 0.05 is
considered significant. Analysis of data will be done as
randomized (the intention-to-treat analysis) and sec-
ondary “as-treated.”
Recruitment
Potential patients are identified by physicians who are
working in abdominal pain clinics at the SolviMáx or the
Maasziekenhuis Pantein and are screened for eligibility.
Patients are then informed on the purpose, nature and
duration of the trial. Following consultation, potential par-
ticipants are allowed 14 days for consideration. If a patient
subsequently consents, they are then randomized by the
principal investigator. Patients are allowed to withdraw
their consent at any given time during the study period.
Discussion
Anterior cutaneous nerve entrapment syndrome
(ACNES) is caused by the entrapment of end branches
of the intercostal nerves that are residing in the abdom-
inal wall. Patients suffer from severe abdominal pain that
is often not recognized as most physicians are focused,
when confronted with abdominal pain, on a visceral
source of the pain [1, 2]. The diagnosis of ACNES is sug-
gested by a specific combination of the patient’s history
(chronic pain) and physical examination (circumscript
pain localization, positive pinch, Carnett’s test and
abnormal sensitivity) and the absence of objective abnor-
malities in either laboratory tests or imaging techniques
searching for possible visceral causes [4]. Once patients
are diagnosed with ACNES, a treatment regimen including
tender-point injections is subsequently offered [4]. If the
pain is recalcitrant, a neurectomy is considered. This treat-
ment algorithm is successful in up to 90% of patients
[5]. Research on minimally invasive treatment options
is exceedingly scarce but may be explored as suggested
[26–28]. Two case reports recently attracted attention
to PRF treatment of the dorsal root ganglion (DRG) as
a potential alternative approach in ACNES resulting in
pain reduction and improvement of quality of life [10,
11]. The present study is the first randomized trial com-
paring PRF and neurectomy in ACNES patients. Results of
this proof-of-concept trial may determine whether PRF
offers an effective treatment option for ACNES.
PRF treatment was initially designed as a less destructive
alternative to RF therapy. The technique is based on the
intermittent administration of high-frequency current
resulting in tissue temperatures below 42 °C, thus prevent-
ing neuronal damage [6, 7]. Initial studies were promising
reporting significantly reduced levels of chronic pain in a
variety of syndromes [8, 9]. However, evidence on its use
on peripheral nerves is scarce. In the present era of
evidence-based medicine, well-designed proof-of-concept
trials are required prior to widespread introduction. PRF
is an example of a popular treatment tool for several
chronic pain conditions although the scientific evidence is
rather limited [29–31]. The effect of PRF may depend on
the type of pain syndrome. Reports on PRF in cervical
radicular pain and lumbosacral radicular pain suggested
major pain relief for more than 3 months, providing level
1B+ and 2C+ evidence, respectively [8, 9]. However, the
use of PRF in other pain entities, such as lumbar zygapo-
physeal joint pain and trigeminal neuralgia, was found to
be less effective than conventional RF [32, 33]. Therefore,
there is a need for high-level evidence studies confirming
the possible beneficial effects of PRF treatment in specified
pain syndromes.
A potential limitation of the present study is its non-
blinded design. However, blinding patients and/or physi-
cians in the present design is practically impossible.
In conclusion, this randomized controlled, proof-of-
concept trial will investigate the possible efficacy of PRF
treatment as a minimally invasive treatment in ACNES
patients. If effective, patients could benefit from its less
invasive character whereby the need for surgery is mini-
mized. High-level evidence on the use of PRF treatment
on peripheral nerve pain syndromes will be increased.
The first study results are expected towards the end of
2017 and will be communicated via a publication.
Trial status
Period of patient recruitment.
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